➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Express Scripts
McKesson
Medtronic
Boehringer Ingelheim

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 6,803,046


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 6,803,046 protect, and when does it expire?

Patent 6,803,046 protects KINEVAC and is included in one NDA.

This patent has ten patent family members in eight countries.

Summary for Patent: 6,803,046
Title: Sincalide formulations
Abstract:The invention features sincalide formulations that include an effective amount of sincalide, a bulking agent/tonicity adjuster, a stabilizer, a surfactant, a chelator, and a buffer. The invention also features kits and methods for preparing improved sincalide formulations, as well as methods for treating, preventing, and diagnosing gall bladder-related disorders using sincalide formulations.
Inventor(s): Metcalfe; Edmund C. (Hillsborough, NJ), Monteferrante; Jo Anna (Raritan Township, NJ), Newborn; Margaret (Hamilton Township, NJ), Ropiak; Irene (Lawrenceville, NJ), Schramm; Ernst (North Brunswick, NJ), White; Gregory W. (Monmouth Junction, NJ), Zodda; Julius P. (Mercerville, NJ)
Assignee: Bracco International B.V. (Amsterdam, NL)
Application Number:10/222,540
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,803,046
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use; Device;

Drugs Protected by US Patent 6,803,046

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bracco KINEVAC sincalide INJECTABLE;INJECTION 017697-001 Approved Prior to Jan 1, 1982 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,803,046

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 502647 ⤷  Free Forever Trial
Australia 2003304382 ⤷  Free Forever Trial
Canada 2503982 ⤷  Free Forever Trial
China 100374154 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Merck
Baxter
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.